Tag: over-the-drugs
-
New data on risk vs benefit for potent CAR-T cancer drugs
A promising but risky new group of customized cancer drugs will be in focus this weekend at the annual meeting of the American Society of Hematology (ASH), where clinical trial results will help clarify their potential for doctors and investors. Experimental chimeric antigen receptor T-cells, or CAR-Ts, are made by genetically altering a patients’ own…
-
U.S. pushes to close lead testing gaps, echoing Reuters report
By Joshua Schneyer and M.B. Pell NEW YORK (Reuters) – U.S. states must do more to ensure that all children enrolled in the Medicaid health care program are tested for lead poisoning, a U.S. Government agency said this week, acknowledging major gaps in screening that were highlighted in a recent Reuters investigation. In a bulletin…